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Short Title: PCDH19 mutations in Female Epilepsy 
 
Communicated by <Please don’t enter> 
 
 
ABSTRACT: Mutations in PCDH19, encoding protocadherin 19 on chromosome X, cause familial 
epilepsy and mental retardation limited to females or Dravet-like syndrome.  Heterozygous females 
are affected while hemizygous males are spared, this unusual mode of inheritance being probably 
due to a mechanism called cellular interference. To extend the mutational and clinical spectra 
associated with PCDH19, we screened 150 unrelated patients (113 females) with febrile and 
afebrile seizures for mutations or rearrangements in the gene. Fifteen novel point mutations were 
identified in 15 female patients (6 sporadic and 9 familial cases). In addition, qPCR revealed two 
whole gene deletions and one partial deletion in 3 sporadic female patients. Clinical features were 
highly variable but included almost constantly a high sensitivity to fever and clusters of brief 
seizures. Interestingly, cognitive functions were normal in several family members of 2 families: 
the familial condition in family 1 was suggestive of Generalized Epilepsy with Febrile Seizures 
Plus (GEFS+) whereas all three affected females had partial cryptogenic epilepsy. These results 
show that mutations in PCDH19 are a relatively frequent cause of epilepsy in females and should 
be considered even in absence of family history and/or mental retardation. ©2010 Wiley-Liss, Inc. 
KEY WORDS: PCDH19, Epilepsy, Febrile seizures, microdeletion, cognitive function 
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INTRODUCTION 
Mutations in the PCDH19 gene, located on chromosome X and encoding the protocadherin 19, were originally 
identified in Epilepsy and mental retardation limited to females (or Epilepsy, Female-restricted, with Mental 
Retardation, EFMR, MIM #300088) (Dibbens, et al., 2008). EFMR is a disorder with a remarkable X-linked 
inheritance: only females with heterozygous mutations are affected whereas males with hemizygous mutations are 
unaffected (Fabisiak and Erickson, 1990; Juberg and Hellman, 1971; Ryan, et al., 1997). This unusual mode of 
inheritance is likely to be due to cellular interference, a mechanism assuming that only the co-existence of 
PCDH19-positive and -negative cells, as a result of random X inactivation in females, is pathogenic (Depienne, et 
al., 2009; Johnson, 1980; Wieland, et al., 2004). 
The phenotype of EFMR varies from mild to severe in terms of seizure type and severity as well as in the 
degree of cognitive impairment (Scheffer, et al., 2008). Seizures begin in infancy or early childhood (6–36 
months) and are sensitive to fever in most patients. Patients present with variable seizure types including tonic-
clonic, tonic, atonic, absences, myoclonic jerks and partial seizures. Behavioral problems are often part of the 
clinical picture and can manifest as autistic, obsessive or aggressive features (Depienne, et al., 2009; Scheffer, et 
al., 2008). Recently, we have shown that the clinical spectrum associated with PCDH19 mutations can overlap that 
of Dravet syndrome (Depienne, et al., 2009). Intellectual outcome was reported to range from normal intellect to 
mental retardation within families; however, all patients reported to date either had intellectual disability or 
belonged to families where cognitive delay was present in other family members (Scheffer, et al., 2008).  
In the present study, we have screened 150 unrelated probands with diverse epilepsy subtypes with or without 
cognitive impairment or mental retardation in order to define the mutational and clinical spectra associated with 
PCDH19 mutations. 
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MATERIALS AND METHODS 
 
Patients 
We selected 150 unrelated probands (113 females and 37 males) for PCDH19 screening. The referral physicians 
filled a detailed clinical questionnaire for every patient and clinical reports were also collected for most patients to 
assess the clinical history of the disease. Ninety-five percent (n=142) of the patients had been initially referred to 
our diagnosis laboratory for genetic testing of SCN1A based on the association of febrile and afebrile seizures. 
Most patients (n=104) had no family history of epilepsy. These sporadic cases include 16 patients with DS in 
whom SCN1A testing was negative. Forty-six probands had at least one relative with epilepsy. The mode of 
inheritance was compatible with that of EFMR in 10 families. Eight families were reported as GEFS+ 
(Generalized Epilepsy with Febrile Seizures Plus) conditions. Eight families had a homogeneous phenotype of 
generalized idiopathic epilepsy (n= 5) or partial epilepsy (n= 3). Informed written consent was obtained from the 
patients’ parents before blood sampling. This study was approved by the ethical committee (CCPPRB of Pitié-
Salpêtrière Hospital, Paris, n°69-03, 25/9/2003).  
 
PCDH19 Screening 
The coding sequence of PCDH19 (transcript reference EF676096) was amplified in 11 fragments, and screened using 
direct sequencing, as already described (Depienne, et al., 2009). Mutations found in patients were directly searched for 
in available parents using direct sequencing of the corresponding amplicon. When the mutation was absent from both 
parents, parental testing was performed using microsatellite markers at the PCDH19 locus to ensure that the mutation 
occurred de novo. In addition, 190 French controls (95 females and 95 males ho were healthy spouses of patients 
with other autosomal dominant diseases) and 200 Polish controls (118 females and 82 males) were included to test 
new variants of the PCDH19 gene. Mutation interpretation and amino acid conservation in orthologs and paralogs was 
assessed using the Alamut 1.31 Software (Interactive Biosoftware) and Clustalw (available at 
http://bioinfo.hku.hk/services/analyseq/cgi-bin/clustalw_in.pl).  
Deletions or duplications involving PCDH19 were searched for using quantitative real-time PCR. Six primer pairs 
(one per exon) were designed using PrimerExpress 1.5 (sequences available on request). Real-time PCR experiments 
were performed using 100 ng of genomic DNA, 0.4 µM of each primer and 12.5 µl of Sybr Green PCR master mix 
(Applied Biosystems) in a total volume of 25 µl. The RNAse P (RNAse P control assay from Applied Biosystems) 
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was used as the reference amplicon. Each sample was run in triplicate on an ABI PRISM 7900 Detection system 
(Applied Biosystems). Relative ratios were calculated using the formula r = 2–∆∆Ct with ∆∆Ct = (Ct Mutation - Ct RNAseP) 
ind tested – (Ct Mutation – Ct RNAseP) ind ref 
 
Characterization of PCDH19 deletions using high density SNP arrays 
Patients with PCDH19 deletions were analyzed using 370CNV-Duo genotyping BeadChip arrays (Illumina). The 
Infinium II Genotyping reaction steps were performed according to the manufacturer’s specifications. Image data 
analysis and automated genotype calling was performed using Beadstudio 3.1 (Illumina). Breakpoints of the deletions 
were defined as the first and last SNP comprised in the region of the deletion, which were homozygous and presented 
a decreased log ratio (in the order of -0.5). 
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RESULTS 
 
Genetic analyses 
One hundred and fifty unrelated probands (113 females and 37 males) were screened for mutations in PCDH19 by 
direct sequencing. A total of 15 different mutations, all novel, were identified at the heterozygous state in 15 
female patients (Tables 1A, Figure 1 and supplementary Fig. 1). Eight were missense variants 
(c.242T>G / p.Leu81Arg; c.437C>G / p.Thr146Arg; c.617T>A / p.Phe206Tyr; c.747A>T / p.Glu249Asp; 
c.1023C>G / p.Asp341Glu; c.1682C>G / p.Pro561Arg; c.1700C>T / p.Pro567Leu; c.1852G>A / p.Asp618Asn), 2 
were nonsense mutations (c.462C>A / p.Tyr154X; c.2656C>T / p.Arg886X), 4 were base pair insertions or 
deletions introducing a frameshift into the protein sequence (c.424delG / p.Ala142ProfsX70; 
c.514dupG / p.Glu172GlyfsX54; c.697_700delinsTAAC / p.Asp233X; c.2019delC / p.Ser674LeufsX2) and one 
was an in-frame duplication of three amino-acids (c.415_423dup / p.Ser139_Ala141dup). All mutations were 
located in exon 1 with the exception of the p.Arg886X nonsense mutation, which was located in exon 4. Missense 
variants all affected amino-acids of the extracellular domain of protocadherin 19, which are highly conserved in 
orthologs and in paralogs of PCDH19 (Supplementary Fig. 2). To confirm that the 15 mutations were pathogenic, 
we screened 190 healthy French individuals. None was found in the control population, supporting their 
deleterious role. Since Family 2, in which the c.437C>G / p.Thr146Arg mutation was identified, was of Polish 
origin, this variant was also tested and not found in 200 healthy Polish Controls. 
Parents of mutated probands and affected relatives were tested for the mutation when available. Six out of the 15 
probands with PCDH19 mutations were isolated cases (families 3, 5, 6, 11, 13 and 14) but both parents were 
available in only 3 families. The mutation was absent in both parents in one family out of the 3, indicating that it 
arose de novo (family 11). Remarkably, in the 2 other families (13 and 14), the mutation was inherited from the 
asymptomatic mother. In familial cases (families 1, 2, 4, 7, 8, 9, 10, 12 and 15), mutations were inherited from a 
healthy father in 3 families (families 2, 9 and 12), leading to a recurrent transmission of the mutation to all the 
daughters. In families 8 and 15, which yet include two affected daughters, the mutations were absent from both 
parents, suggesting germinal mosaicism in one parent. However, the sister of the proband was unavailable for 
genetic analysis in both families, so it remains uncertain whether the affected sisters had the same mutation than 
the proband. In families 1, 4 and 10, the mutation was inherited from an affected mother and segregated with the 
disease in all affected family members. It was not possible to determine the origin of the mutation in the remaining 
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families (families 3, 5, 6, and 7) although the presence of an affected maternal aunt in family 7 argued in favour of 
paternal inheritance.  
In order to uncover micro-rearrangements in PCDH19 that could have been missed by direct sequencing, we 
developed quantitative real-time PCR assays to measure the copy number of each exon of the gene. This analysis 
identified two whole gene deletions and a partial deletion spanning exons 1 to 3, in 3 additional female patients 
(Figure 2 and Table 1B). Analysis of the corresponding patients’ DNA using high density SNP array revealed that 
the deletions had different size and breakpoints. The whole gene deletions in patients N07 0897 (family 17) and 
N07 1329 (Family 18) spanned 0.5 and 6.3 Mb, respectively, and comprises nearby genes (Figure 3). The largest 
deletion encompasses DIAPH2, a gene possibly involved in oogenesis and associated with premature ovarian 
failure type 2 (Bione, et al., 1998). The 0.5 Mb deletion includes TNMD, TSPAN6, SYTL4 and SRPX2, the gene 
responsible for X-linked recessive rolandic seizures associated with oral and speech dyspraxia and mental 
retardation (Roll, et al., 2006). Contrary to the two other deletions, deletion of exons 1 to 3 was limited to the 
PCDH19 gene in patient N08 0125 (family 16). Parents of the proband were unavailable in family 17 but analysis 
of the parents in families 16 and 18 revealed that the deletions arose de novo. 
 
Summary of clinical features for PCDH19-positive patients  
The clinical features of PCDH19-positive patients are summarized in Table 2. The clinical pictures were variable 
from one patient to another. However, seizures were highly sensitive to fever in most patients, especially in the 2 
first years of life and during childhood. Another characteristic feature observed in PCDH19-positive patients was 
seizures occurring in clusters (2-10 seizures per day, lasting over several days). Remarkably, cognitive functions 
ranged from normal to severe intellectual deficiency. Indeed, several or all family members of 2 families (families 
1 and 2) had no cognitive impairment.  
 
Case reports 
Family 1, of French origin, includes 4 female patients. Neonatal periods were uneventful for all patients. The 
proband (N05 0550) was a 6-year-old girl. Her affected mother was treated with Phenobarbital (PB) during her 
whole pregnancy. GTCS, lasting ~20 seconds and occurring in clusters of 5-10 seizures per day, have appeared at 
11 months of age, after a febrile episode. Clusters of seizures have persisted for 10 days. Neurological status of the 
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patient was normal between seizures. Clinical investigations, including search for infectious agents, lumbar 
puncture and CT scan, were normal. Seizures persisted but became rarer when the patient was treated with sodium 
valproate (VPA) and Clobazam (CLB), and finally stopped with PB. Later on, GTCS became very rare, occurring 
most often in afebrile contexts, but absence episodes were sometimes observed. EEGs were normal. Psychomotor 
development of the patient was normal and she had no school difficulties at 6 years of age. She was still treated by 
PB at the time of the study. Her mother (N05 0548) was 28 years old at the time of the study. At 18 months of age, 
while she was febrile, she presented a cluster of 4-5 brief GTCS per day that lasted for several days. Later on, 
febrile or afebrile GTCS regularly recurred until age 7. VPA appeared inefficient but GTCS finally ceased when 
she was treated with PB. However, absence episodes, mostly triggered by fatigue were observed. EEGs and 
cerebral MRI were normal. The maternal grandmother of the proband (N05 0549) was 54 years old when 
examined for the last time. As her daughter, she has had a cluster of GTCS lasting several days at 18 months of 
age although it remained uncertain whether she was febrile or not at this time. GTCS persisted until age 10, and 
then absences occurred from age 15. Myoclonic jerks were also noticed during adolescence. VPA was inefficient 
but PB allowed a reasonable control of the seizures. She was still treated with PB at the time of the study. Her 
psychomotor development had always been normal and no cognitive deficit was perceptible. EEGs and cerebral 
MRI remained unavailable. The maternal aunt of the proband (N09 2223), was 36 years old when examined. At 18 
months of age, she developed febrile status epilepticus without later motor deficit but secondary psychomotor 
decline. When she was 10, she developed afebrile GTCS and transient losses of consciousness (suggesting either 
absences or partial seizures). She always had school difficulties and developed psychotic manifestations. At the 
time of the study, she presented with moderate intellectual deficiency. EEGs during childhood were unavailable 
but those during adulthood were normal. MRI was normal. During childhood, she was treated with PB which 
appeared effective. In adulthood, carbamazepine (CBZ) was ineffective but she finally became seizure-free under 
VPA. She was still treated with VPA at the time of the study. 
 
Family 2 was of polish Ashkenazi origin on the paternal side. There was no family history of seizures or cognitive 
impairment in the previous generations. The three patients were born after uneventful pregnancies and had normal 
neonatal periods. None of them had psychiatric features and neurological examination always remained normal. 
Patient N09 2853 was 24 years old at the time of the study. Since the age of 7 months, seizures occurred in clusters 
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lasting a few minutes, with symptoms consisting of sudden cry and behaviour changes. There were one or two 
clusters per months, frequently favoured by hyperthermia. Brain MRI, at 5 years of age showed a frontal median 
dermoid cyst. She underwent resection of the cyst without any modification of seizure frequency. From the age of 
9 years, the seizure semiology was modified, starting with a short yell or the repetition of a word related to the 
events of the previous days and followed by hyperactivity, fear, pallor and tachycardia. Consciousness was not 
altered during the shorter episodes. Clusters including more than 10 daily seizure episodes occurred over 2 to 3 
days with intervals of 6 weeks to 3 months. They occurred mostly during daytime or as she fell asleep and were 
currently triggered by fever, emotions or sleep deprivation. She frequently experienced right frontal headache 
during the days preceding the seizures. At the age of 10 years, stereoencephalography showed rapid spikes 
followed by slow spike-waves in the left frontal cortex with contralateral propagation. The diagnosis of 
cryptogenic partial frontal epilepsy was considered. She has been treated with CBZ from the age of three years to 
the age of nineteen years in addition to other successive drugs (VPA, VGB, LTG, TPM and LEV). Seizure offset 
occurred when she was 19 years old, as she was treated with CBZ and LEV, whose doses were then progressively 
decreased. Neuropsychological testing, at the age of 16 years showed a VIQ score of 115 and a PIQ score of 87 
with slight impairment in working memory and visual treatment. She is now 23 years old and is attending the 
courses of French engineering school. 
Patient N09 2265 was one year younger than her sister.  She experienced a first cluster of GTCS lasting one hour, 
when she was five years old, 12 hours after a febrile episode. At 6 years, she had two similar clusters favoured by 
hyperthermia as well as several afebrile nocturnal episodes. Neuropsychological testing, when she was 7 years old 
showed a VIQ score of 117. She continued to experience repeated clusters of seizures with a modified semiology 
including automatic gestures, chewing and elevation of the left arm. Seizures were mainly triggered by fever. 
Some nocturnal tonic-clonic seizures also occurred. She was first treated with VPA, which was substituted with 
CBZ at the age of 10 years. Treatment could be stopped 6 years later. Now aged 22 years, she attends the classes 
of a French engineering school as her sister. 
The youngest sister (N09 2851) was 15 at the time of the study. Since 9 months of age, she experienced clusters of 
GTCS during febrile episodes as well as nocturnal seizures with a semiology consisting of straightening up of the 
body, incoherent language, hypertonia with hand contractions, deviation of the head (mainly on the right), chewing 
and bruxism. Seizure semiology was progressively modified with staring, back dropping and yelling, clonic 
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movements followed by hypertonia with ocular revulsion and chewing. EEG was in favour of a possible fronto-
temporal origin. She has first been treated with CBZ. LTG was added when she was 7 years old and CBZ was 
switched to LEV two years later. Seizure offset occurred at 13 years of age. When seen for the last time, she was 
attending normal school although she displays slight reduced processing speed. She has won several 
championships of bridge. 
 
Family 4, of French origin, included 3 female patients who all had GTCS but detailed clinical data were available 
for the proband only (N09 0418). She was born after uneventful pregnancy and had a normal development before 
the onset of seizures. She experienced a first brief generalized febrile seizure at 13 months. Two weeks later, she 
had a cluster of brief GTCS without fever and a treatment by VPA and Clonazepam (CLN) was started. At the age 
of 3 years, she had several generalized seizures in clusters. Seizures were brief (< 2 minutes) but repeated over 
several days (3-4 days). Afterwards, she had occasional episodes of GTCS occurring in cluster, which were 
commonly triggered by fever and lasted one or two minutes or even only a few seconds. VPA was replaced by 
TPM for a better control of the seizures. She never had myoclonia or partial seizures. At the age of 6 year, her 
language was delayed but she was able to make simple sentences. She was described as an introverted child, who 
had difficulties to establish social interactions. She was capable of communicating with words but did not use 
language spontaneously. For instance, she preferred pointing at objects or images rather than naming them. When 
examined for the last time, at 7 years old, she had a mild cognitive and language delay. Her mother was reported to 
have generalized seizures between age 2 and 6 years, that were first treated by PB and later on by VPA. At that 
time, polyspike-wave discharges were observed on EEGs. At the age of 18 years, she became free of seizures 
without treatment. However, when examined at age 44, she presented with mild intellectual disability. The half-
sister of the proband had 3 “Grand Mal” seizures at the age of 5 years old without fever. She became free of 
seizures when treated with VPA. However, during the adolescence, she presented with important scholar 
difficulties and psychiatric instability. 
 
Family 12 includes two affected sisters born from non consanguineous parents of French origin. Both sisters have 
had intra-uterine growth retardation related to a homozygous variant of the methylenetetrahydrofolate reductase 
gene in the mother. However, they were considered healthy full-term newborns. The proband (N08 0696), who 
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was 4 years old at the time of the study, experienced her first seizures at 11 months during a febrile otitis episode. 
She had about 10 febrile GTCS lasting a few minutes the same day with normal examination in-between, normal 
interictal EEG and normal brain MRI. Another series of afebrile paroxysmal events, characterized by numerous 
absences without abnormal movements lasting less than a minute, occurred one week later despite the initiation of 
VPA therapy. CLB was therefore added to VPA. Three more clusters of 5-10 seizures occurred at the ages of 2, 3 
and 4 years, requiring an add-on treatment with LTG. The clinical manifestations were heterogeneous, including 
absences, clonic and tonic seizures, sometimes associated with eyes turning. Most seizures lasted 1 to 5 minutes, 
but clusters of 10 to 15 minute-long seizures were also observed. Interictal EEGs remained normal except for 
occasional posterior slow waves. At the age of 3.5 years, psychomotor retardation and language delay became 
evident. She also had a mild microcephaly (-2 SD). The youngest sister (N 09 1103) was 2.5 years old at the time 
of the study. She had a first cluster of ~10 afebrile GTCS at 8.5 months, leading to a treatment by VPA. Brain MRI 
was normal and interictal EEG revealed bitemporal slow waves but no paroxysmal activity. Another seizure 
cluster occurred a few days later and VGB was added to VPA. Two more episodes of 8-10 afebrile seizures 
occurred at the age of 21 months and were characterized by generalized tonic manifestations, sometimes 
asymmetrical with head turning, lasting a few minutes. EEG recording of a seizure showed generalized discharges 
from the beginning of the seizure. After replacement of VGB by TPM, no other seizures occurred. Her 
psychomotor development was slightly retarded, as she sat alone at 13 months, walked independently at 18, but 
her speech ability was relatively preserved at the age of 2. Her head growth followed the -2 SD curve until 6 
months then slowed down to -2.5 /-3 SD. 
 
Family 17 was of French origin and included a single affected female patient (N07 0897) who was 7 years old at 
the time of the study. Her parents were reported to be healthful and there was no further history of febrile seizures 
or epilepsy in the family. The proband was born after an uneventful pregnancy and had a normal development 
before the onset of seizures. At 15 months, while she was febrile, she started having clusters of brief generalized 
tonic seizures that required hospitalization. A treatment by VPA was set up but tonic seizures lasting 2-3 minutes 
and repeating during several days recurred at 19 months in a febrile context. Despite the successive introduction of 
multiple AEDs (CLB, TPM, PB and PHT), brief hypertonic seizures occurring in clusters persisted over time. An 
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EEG performed at 19 months was normal. At 5 years old, she had a normal neurologic examination but showed a 
global developmental delay predominating in language and learning (estimated to a one-year delay). 
 
The proband of family 18 was born at 36 weeks from a bichorionic gemellar pregnancy. Her parents, her twin 
sister and a youngest sister were all healthy. Her psychomotor development was normal until the onset of seizures. 
She experienced a first afebrile generalized convulsive status epilepticus at the age of 14 months. Investigations 
including brain imaging, lumbar puncture, toxic and metabolic screenings were normal. EEG was normal. She was 
treated with CLN and VPA. She started walking at 16 months, almost two months after her twin sister. She had 
new episodes of febrile GTCS at 1.5, 2.5 and 3.5 years. Behavioural disturbances and language delay became 
obvious around 3 years old. A decrease in CLN dosage at the age of 4 years led to a new status epilepticus and 
LTG was added to CLN and VPA. Likewise, a decrease in VPA dosage at the age of 5 years was unsuccessful. 
From the age of 5 years, she had several clusters of GTC seizures, most of them triggered by mild fever. At the age 
of 7 years, she had a moderate cognitive impairment including a global executive dysfunction. Karyotyping was 
normal and search for X-Fragile expansion was negative. Diurnal and nocturnal EEGs and Brain MRI remained 
normal. A novel attempt to decrease CLN dosage at 7 years led to the recurrence of afebrile seizures in clusters. 
CLN was replaced by CLB. At the time of the study (11 years), she was free of seizures since age 9 on tritherapy 
(VPA, CLB, TPM). She was able to read and her language appeared normal. However, she had major behavioural 
and personality disturbances. She also had difficulties with logical reasoning and graphics. She never had ataxia or 
myoclonic jerks and her seizures were photoinsensitive. 
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DISCUSSION 
 
In this study, we report 15 novel point mutations and three deletions in the PCDH19 gene in 18 unrelated female 
patients, for an overall mutation frequency reaching 16% (18/113). We also tested 37 male patients in this study 
but no mutation was found. However, we cannot exclude that mosaicism has been missed by screening only DNA 
extracted from blood cells in these patients. 
Although all the previously reported mutations were clustered in exon 1 of PCDH19 (corresponding to the extra-
cellular cadherin domain of protocadherin 19) (Depienne, et al., 2009; Dibbens, et al., 2008; Hynes, et al., 2009), 
we now report a nonsense mutation in exon 4 (p.Arg886X) that segregated in several affected members of family 
1. This shows that the PCDH19 mutational spectrum is not limited to mutations in exon 1. Furthermore, two whole 
gene deletions and one partial deletion were identified using quantitative real-time PCR. These deletions constitute 
the first micro-rearrangements involving PCDH19 identified in female patients with febrile seizures and epilepsy. 
Altogether, these results confirm that mutations in PCDH19 are associated with a loss-of-function of protocadherin 
19 in cells that have inactivated the normal X chromosome, and that screening of PCDH19 should include a 
specific method to search for rearrangements in addition to direct sequencing of the whole coding sequence. 
As previously reported, the phenotype of the patients with PCDH19 mutations was highly variable between 
families but also within affected members of a same family (Table 2). This variability includes the age at onset 
(mean age at onset: 16 months, ranging from 7 months to 5 years), the occurrence of status epilepticus episodes 
(42%, 10/24), the response to AEDs (pharmacoresistance in 76% of the cases, 19/25) and the temporal evolution 
of the patients. However, seizures occurring in cluster (92%, 23/25 patients) and a high sensitivity to fever (90%, 
20/22 patients) were almost invariably present in PCDH19-positive patients. All patients have had generalized 
seizures (although in some cases, the generalized seizures were only in febrile contexts) and 68% exhibited 
multiple seizure types (17/25) including partial seizures (of frontal or temporal origin) and atypical absences. 
Although seizures appeared highly resistant to AEDs during the first years of life, the frequency and 
pharmacoresistance of seizures tended to decrease over time, and some patients were even free of seizures during 
adolescence or adulthood on monotherapy. Myoclonic jerks were infrequent in patients with PCDH19 mutations 
(9%, 2/23) and photosensitivity was reported in only one case out of 25 (<5%). In contrast, a high frequency of 
behavioral disturbances, including autistic features, was noticeable (28%, 7/25 patients). In some patients, social 
withdrawal or personality troubles were even the most prominent and disabling feature when the children became 
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older. Interestingly, the phenotypes of the patients with PCDH19 deletions seemed indistinguishable from those 
with point mutations although this finding needs to be confirmed with a larger number of patients carrying 
deletions.  
Intellectual deficiency was also very variable from one patient to another: cognitive impairment was reported to be 
mild in 6 patients, moderate in 10, and moderate/severe in 2 patients. One patient was too young to evaluate her 
cognitive status (family 7). Interestingly, in families 1 and 2, most or all patients presented without cognitive 
impairment. In family 2 for instance, all the 3 sisters with the p.Thr146Arg mutation had normal cognitive 
abilities. The history of epilepsy in the 3 sisters was nevertheless similar to other patients with moderate mental 
retardation and included in particular many seizures in cluster during childhood, persistence of the seizures despite 
polytherapy and later development of partial seizures of frontal or temporal origin. This highly suggests that the 
cognitive prognosis is not related to the severity of epilepsy. In family 1, the history of febrile and afebrile seizures 
in the proband, her mother and her grand-mother was highly suggestive of Generalized Epilepsy with Febrile 
Seizures plus (or Genetic Epilepsy with Febrile Seizures plus, GEFS+, MIM #604233) (Scheffer and Berkovic, 
1997). It is unclear so far whether the favorable cognitive outcome in these patients is due to the mutation itself, 
which could have milder functional consequences on the protocadherin 19. The large intrafamilial variability of 
the phenotype (in particular in family 1) however suggests that other genetic or non genetic modifier factors could 
be involved as well. One attractive hypothesis is that this phenotypic variability could be due to random or skewed 
X inactivation. Cellular interference is based on the random X inactivation resulting in a functional mosaicism in 
females (Compagni, et al., 2003; Depienne, et al., 2009; Johnson, 1980; Wieland, et al., 2004). A totally skewed X 
inactivation in neurons would theoretically leads to a homogenous cell population (expressing or not the normal 
protocadherin 19), corresponding to a non-pathogenic situation. It is possible that a partially skewed X inactivation 
(such as 60:40, 70:30 or 80:20) could represent situations less severe than a random X inactivation (50:50) where 
the cellular interference is expected to be the highest. The severity of the epilepsy could therefore be correlated 
with the relative amount of inactivated neurons for each chromosome in the brain and some mutation carriers, like 
mutated mothers in family 13 and 14 for example, could even be asymptomatic due to totally skewed X 
inactivation.  
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The wide phenotypic expression associated with PCDH19 mutations is very reminiscent of what is observed for 
patients with SCN1A mutations. It is now well-established that SCN1A mutations are associated with a large 
clinical spectrum ranging from febrile seizures only to typical or atypical Dravet syndrome (Depienne, et al., 2010; 
Harkin, et al., 2007). We have previously reported that the similarity between PCDH19 and SCN1A clinical 
spectra comprises Dravet syndrome; now, we show that it also extends to that of GEFS+. Indeed, intellectual 
disability as well as partial epilepsy can also be part of SCN1A-positive GEFS+ families (Depienne, et al., 2010; 
Escayg, et al., 2000). Differentiating one condition to the other would therefore be difficult in some cases. 
However, some clinical features could help prioritizing the analysis: for instance female patients with an age at 
onset after 12 months and presenting with seizure clusters should be first screened for PCDH19 mutations, 
especially when the families include several females but no male patients. Regarding Dravet Syndrome, screening 
for PCDH19 mutations should be performed for female patients when analysis of SCN1A (including a method 
searching for SCN1A micro-rearrangements) is negative. 
Given the unusual mode of inheritance and the wide phenotypic variability associated with PCDH19, genetic 
counseling appears delicate. In the case of mutations inherited from an asymptomatic father, all the daughters are 
expected to be affected. Therefore, taking into account the frequent bad cognitive prognosis, it could be possible to 
offer a prenatal diagnosis using only a fetal sex determination from maternal blood (Wright and Burton, 2009). 
Female patients with PCDH19 mutations have a 50% risk to transmit the mutation but only the females would be 
affected, for a global risk of 25%. However, in some situations, genetic counseling could be even more difficult, 
such as in family 17 in which the proband had a PCDH19 deletion encompassing other nearby genes with a 
recessive X-linked inheritance such as SRPX2. In that case, the patient will have a 25% risk to have an affected 
daughter and of a 25% risk to have a son affected with a phenotype of variable severity including rolandic 
epilepsy, oral and speech dyspraxia, mental retardation and perisylvian polymicrogyria. 
In conclusion, these results extend the mutational and clinical spectra associated with PCDH19-related epilepsies 
and show that mutations in PCDH19 are a frequent cause of epilepsy in females and should be considered even in 
absence of family history and/or mental retardation.  
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Family Patients (proband) Exon Amino acid changes 
Consequence at the protein 
level Parents' analysis 
Associated 
polymorphisms 
3 N 09 0176 1 c.242 T>G p.Leu81Arg Unknown none 
4 N 09 0418 1 c.415_423 dup p.Ser139_Ala141dup Maternal inheritance none 
5 N 09 1326 1 c.424 delG p.Ala142ProfsX70 Unknown none 
2 N09 2861 1 c.437 C>G  p.Thr146Arg Paternal inheritance c.1627 C>T / p.Leu543Leu 
6 N 09 1568 1 c.462 C>A p.Tyr154X Unknown none 
7 N 09 1461 1 c.514dupG p.Glu172GlyfsX54 Unknown (paternal inheritance 
expected) none 
8 N 05 1365 1 c.617 T>A p.Phe206Tyr De novo (mosaicism in one parent?) c.3447+ 8 T>C 
9 N 08 1081 1 c.697_700delinsTAAC p.Asp233X Paternal inheritance none 
10 N 08 1391 1 c.747 A>T p.Glu249Asp Maternal inheritance c.1627 C>T / p.Leu543Leu 
11 N 09 1071 1 c.1023 C>G p.Asp341Glu De novo none 
12 N 08 0696 1 c.1682 C>G  p.Pro561Arg Paternal inheritance none 
13 N 09 1090 1 c.1700 C>T p.Pro567Leu Maternal inheritance none 
14 N 08 1063 1 c.1852 G>A  p.Asp618Asn Maternal inheritance c.1627 C>T / p.Leu543Leu 
15 N 09 1135 1 c.2019 delC p.Ser674LeufsX2 De novo (mosaicism in one parent?) none 
1 N 05 0550 4 c.2656 C>T  p.Arg886X Maternal inheritance c.1627 C>T / p.Leu543Leu 
Table 1A: Female patients with point mutations identified by direct sequencing 
 
Family Patients Exon Quantitative PCR Consequence at the protein level Parents' analysis 
Associated 
polymorphisms 
16 N 08 0125 1 to 3 deletion of exons 1 to 3 Absence of protein synthesis? De novo none 
17 N 07 0897 1 to 6 Whole gene deletion Absence of protein synthesis Unknown none  
18 N 07 1329 1 to 6 Whole gene deletion Absence of protein synthesis De novo none  
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Table 1B: Female patients with deletions identified by semi-quantitative real-time PCR 
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Family Patient Number 
Age at 
exam 
(years) 
Age at 
first 
seizure 
(months) 
Type of the 
first seizure Type of seizures SE 
Sz in 
cluster Myocl. 
Pho 
Sen. 
Sensitivity 
to fever Ataxia ID or PD Language 
AEDs  
(+) 
AEDs 
without 
effects 
AEDs  
(-) Others 
1 N05 0550 6 11 Febrile GTCS 
Febrile and 
afebrile GTCS 
Absences 
no yes no no + no none normal PB VPA - - 
1 N05 0548 28 18 Febrile GTCS 
Febrile and 
afebrile CTGC, 
absences 
no yes no no ++ no none normal PB VPA - - 
1 N05 0549 54 18 GTCS GTCS, absences no yes yes NA NA no none normal PB VPA - - 
1 N09 2223 
 
36 18 Prolonged febrile GTCS 
Febrile and 
afebrile, 
GTCS, 
loss of 
consciousness 
(absences or 
partial sz?) 
Yes (first 
sz) yes no no ++ no moderate normal PB, VPA - CBZ 
Behaviour 
disturbances  
2 N09 2853 24 7 Febrile GTCS 
GTCS 
Partial sz no yes no no +++ no none normal CBZ, LEV 
VPA, 
VGB, 
LTG, 
TPM 
- - 
2 N09 2265 23 60 Febrile GTCS 
GTCS 
Partial sz no yes no no +++ no none normal CBZ VPA - - 
2 N09 2851 15 9 afebrile  GTCS 
GTCS 
Partial sz no yes no No +++ no none normal LTG, LEV CBZ - - 
3 N09 0176 12 11 Febrile GTCS GTCS  yes yes NA   NA +++ ?  mild 
words-
sentences 
 VPA, 
CLB -  LTG  
Behaviour 
disturbances  
4 N09 0418 7 13 Febrile GTCS GTCS  no yes no no +++ no mild 
Delayed 
(sentence
s) 
CLN, 
TPM,  VPA - 
Behaviour 
disturbances  
5 N09 1326 (DS) 20 10 
 Afebrile 
prolonged 
GTCS 
Febrile and 
afebrile GTCS   
partial sz 
yes yes  no no  +++ no moderate words-
sentences 
TPM, 
LEV, ZNS 
 CBZ, 
PB, VPA, 
LTG  
 
Behaviour 
disturbances  
6 N09 1568 9 13 NA GTCS no yes no no +++ no Very mild NA VPA, CLN  - -  - 
7 N09 1461 1 8 afebrile GTCS GTCS  no yes  NA NA NA 
too 
young too young too young NA 
VPA, 
PHT -  
 Slight 
dysmorphic 
features 
8 N05 1365 13 60 afebrile 
Hemiclonic, 
Partial sz, 
Absences 
yes yes no no + yes moderate sentences LTG, CBZ VPA -  -  
9 N09 1515 14 24 
 Febrile 
Complex 
partial hemi 
clonic, 
generalised 
Motor complex 
partial 2nd 
generalised 
yes yes  no  no  ++ subtle moderate  sentences LEV, TPM  VGB  LTG Behaviour disturbances 
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9 N09 1516 13 8 Febrile 
Motor complex 
partial 2nd 
generalised 
yes yes no no ++ subtle moderate sentences 
LEV, 
TPM, 
CLN 
VGB - - 
10 N08 1391 7 8 
febrile, 
generalized, 
in cluster 
Generalized sz 
Partial sz no yes no no +++ yes moderate 
words-
sentences 
PB, TPM, 
CLN, LEV 
STP 
LTG, 
CBZ, 
VPA 
VGB Fatiguability 
11 N09 1071 10 NA NA Partial sz GTCS  NA yes  no NA   NA  NA mild 
 words-
sentences 
CLN, 
LTG, PB -  -  -  
12 N08 0696 4 11 febrile, GTCS 
GTCS, Absences 
Partial sz yes no no no ++ no mild 
words-
sentences VPA, CLB  - -  -  
12 N09 1103 2.5 8.5 
afebrile, 
generalized 
tonic 
atypical 
absences, tonic, 
GTCS 
no no no no no no mild words-
sentences 
TPM, 
VPA, CLN - - 
acquired 
microcephaly 
13 N09 1090 14 15  Febrile GTCS 
brief febrile 
GTCS, atypic 
absences 
Myoclonic jerks  
No but 
prolonged 
sz (15 min) 
yes  yes  yes  +++  yes  moderate/ 
severe  
sentences  
VPA, 
LTG, 
CLB, 
LEV ? 
-  -  -  
14 N08 1063 2 8 febrile, GTCS 
Clonic sz 
Atonic seizures no yes no no no 
too 
young ? 
moderate 
 
less than 
10 isolated 
words at 
2y 
VPA, CLB  - - 
Delayed fine 
motor skills, 
 Delayed 
myelination 
15 N09 1135 6 9 afebrile, generalized GTCS yes yes no no +++ yes moderate 
words-
sentences 
VPA, 
CLB, LTG TPM CBZ -  
16 N08 0125 17 9 Generalized Generalized  yes yes no no +++ no moderate/s
evere 
? VGB, TPM, NTZ  - -  
Behaviour 
disturbances 
17 N07 0897 7 15 
febrile, 
generalized, 
in cluster 
 Generalized  
Hypertonic no yes no NA +++ no moderate 
words-
sentences 
VPA, 
TPM, 
CLB 
PB, PHT -  - 
18 N07 1329 11 14 Afebrile generalized  GTCS  
 Yes (first 
sz)  yes  no no   +++  no  moderate normal 
VPA, 
TPM, 
CLB, 
LTG, CLN 
 -  -   
Delayed fine 
motor skills, 
Behaviour 
disturbances   
Table 2: Clinical features of patients with PCDH19 mutations or deletions 
SE: Status Epilepticus ; ID: Intellectual deficiency; PD: psychomotor delay ; Sz: Seizures; Myocl. : Myoclonic jerks ; Pho Sen. : Seizure photosensitivity ; AEDS : Antiepileptic 
drugs ; AEDs (+) : AEDs with positive response ; wo: without; AEDs(-) : AEDs with negative response (worsening of the seizures or of the patient state) ; GTCS : Generalized 
tonic clonic seizures ; NA: Not available ; CBZ : Carbamazepine, CLB: Clobazam, CLN: Clonazepam , LEV : Levetiracetam,  LTG: Lamotrigine, NTZ: Nitrazepam,  PB: 
Phenobarbital, PHT: phenytoin,  STP : Stiripentol, TPM : topiramate, VGB: Vigabatrin, VPA : Sodium Valproate, ZNS: zonisamide. 
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Identification of 3 families with PCDH19 mutations, in which the majority of patients had normal 
cognitive functions.  A) Pedigrees of the families and segregation analysis of the PCDH19 mutations; 
m/+ and m indicate individuals heterozygous and hemizygous for the mutation, respectively; +/+ 
and + indicate individuals homozygous and hemizygous for the wild-type allele, respectively. 
Squares represent males, circles females; Upper right black corner: Generalized seizures; Upper left 
black corner: Partial seizures; Lower right black corner: FS; Lower left black corner: intellectual 
disability; Grey symbols: Epilepsy of unknown type. Dots in the middle of the squares indicate 
unaffected mutation carriers. The arrows indicate the index cases. B) Sequence electrophoregrams 
of the mutations. The mutation nomenclature is based on th  PCDH19 transcript reference 
EF676096. Nucleotides are numbered according to the cDNA with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence, according to the guidelines 
(www.hgvs.org/mutnomen).  
283x209mm (300 x 300 DPI)  
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Identification of 3 families with PCDH19 deletions.  A) Pedigrees of the families and segregation 
analysis of the PCDH19 deletions; del/+ indicates individuals heterozygous for the deletion; +/+ 
and +, individuals homozygous and hemizygous for the wild-type allele, respectively. Upper right 
black corner: Generalized seizures; Upper left black corner: Partial seizures; Lower right black 
corner: FS; Lower left black corner: intellectual disability; hatched symbols: patients with rolandic 
epilepsy. The arrows indicate the index cases. B) Results of copy number dosage for each exon of 
PCDH19 using real time-Q-PCR. WT1 is a control female; WT2 is a control male.  
283x209mm (300 x 300 DPI)  
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Characterization of the size and breakpoints of the PCDH19 deletions using high-density SNP arrays 
(Illumina). A) Log R profiles of the 3 patients with deletions. The X-axis indicates the position on the 
chromosome X and the Y-axis indicates the log R. The grey stripes represent the location of the 
PCDH19 gene. B) Schematic representation of the deletions indicated by double arrows. The size of 
the deleted regions (in Mb of Kb) is indicated in brackets.  
283x209mm (300 x 300 DPI)  
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Pedigrees of the families and segregation analysis of the PCDH19 mutations in families 3 to 15. m/+ 
and m indicate individuals heterozygous and hemizygous for the mutation, respectively; +/+ and + 
indicate individuals homozygous and hemizygous for the wild-type allele, respectively. Squares 
represent males, circles females; Upper right black corner: Generalized seizures; Upper left black 
corner: Partial seizures; Lower right black corner: FS; Lower left black corner: intellectual disability. 
Right black half (mother of the proband, family 10): Febrile seizures (FS) and tonic clonic seizures 
in childhood, normal cognitive abilitie; Grey symbols: Epilepsy of unknown type. Dots in the middle 
of the squares indicate unaffected mutation carriers. The arrows indicate the index cases. B) 
Sequence electrophoregrams of the mutations. The mutation nomenclature is based on the PCDH19 
transcript reference EF676096.  
283x209mm (300 x 300 DPI)  
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Orthologous and paralogous protein alignments, showing the high conservation of each amino-acid 
altered by missense mutations in vertebrates and in the delta protocadherin paralogous genes.  
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